Csl Behring US - PA Montgomery, King Of Prussia 19406

Csl Behring US entered the industry of Blood Derivatives in 1996 and has grown to employ 1 to 4 people, generating an annual revenue of Over $1 Billion. The NAICS classifies this business under the code 4242101, which describes it as a Blood Derivatives. For further clarification, the SIC classifies this business under the code 2836 and described it as a Blood Derivatives. The business provides service to the B2B market.

To acquire more information, please contact Peter Turner, President by calling (610) 878-4000 during business hours. You can also write to the business’ Headquarters at 1020 1st Avenue, King Of Prussia, Pennsylvania PA 19406. You can also visit the company’s website at cslbehring-us.com. View this business’ social media profiles on Twitter or on Facebbok .

Company: Csl Behring US
Representative: Peter Turner, President
Place of Business: 1020 1st Avenue, King Of Prussia, PA 19406
Contact Number: (610) 878-4000
Website: cslbehring-us.com
Type of Service: Blood Derivatives
SIC Number: 2836
NAICS Number: 4242101
Locality: Headquarters
Market Type: B2B (Business to Business)
Began: 1996
Income/Year: Over $1 Billion
Laborers: 1 to 4
Share This Company:

Csl Behring US is a company operating from Montgomery, Pennsylvania providing professional Blood Derivatives and relevant B2B variables. It was founded in 1996 and registered with the SIC code 2836 as Blood Derivatives, and with the NAICS code 4242101 as Blood Derivatives.

With a current employee count of 1 to 4, Csl Behring US has gone to report making Over $1 Billion per annum on its journey towards growth. This company invites you to contact its representative Peter Turner, President at (610) 878-4000 for related queries, or to locate its Headquarters using the coordinates 40.095162,-75.410346.

The Headquarters can also be found at the street address 1020 1st Avenue in King Of Prussia, Pennsylvania 19406 and can be engaged online through the company website at cslbehring-us.com, the company Twitter , and Facebook page .